Myeloma Minute: Latest Cancer Research Viewed Through a Myeloma Lens
| INNOVATION | Dr. Durie's Blog In the News: Early Diagnosis, CRISPR Gene-Editing, and CAR T-Cell TherapiesWhat does the new cancer research mean for patients? IMF Chairman Dr. Brian G.M. Durie sees a fresh take on MGUS, the curative potential of cloning, and questions on the value of early diagnosis. |
||
| MEDICAL | Staff Update |
| ACTION | Fundraiser |
|
Dr. Joseph Mikhael Joins the IMF |
A Journey Into the Five Senses |
|
World-renowned myeloma expert Dr. Joseph Mikhael has joined the IMF as Chief Medical Officer. Dr. Mikhael will be working closely with Dr. Brian Durie, the IMF's Chair of the Board, to advance the mission of the organization and improve lives of patients with multiple myeloma. |
Accomplished artist Claudia Meyer hosts her solo art show “Sensoria” at the Castelli Art Space at 5440 W. Washington Blvd. in Los Angeles from February 3-11, 2018. A portion of all sales of her works from this event will benefit the IMF. |
|
| INNOVATION | Latest Research FDA Adds Overall Survival Data to Kyprolis LabelThe Food and Drug Administration (FDA) approved adding “overall survival data from the phase III head-to-head ENDEAVOR trial to the Prescribing Information for Kyprolis® (carfilzomib).” Learn more from this press release and about the ENDEAVOR trial. FDA Gives Priority Review to Daratumumab in Frontline MyelomaThe Food and Drug Administration (FDA) grants “Priority Review to the supplemental Biologics License Application (sBLA) for the use of Darzalex® (daratumumab) in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).” |
||
| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series |
||
CLINICAL TRIALS |
EVENTS |
|
New selinexor STORM Trial: Learn How to Participate New ARROW Clinical Trials: Learn How to Participate New ixazomib Clinical Trials: Learn How to Participate Join the conversation about myeloma on the Smart Patients Message Board |
Listen to a Replay: Best of ASH 2017 teleconference February 3, 2018 February 25, 2018 February 25, 2018 March 10, 2018 March 16-17, 2018 April 21, 2018
|
|
Amgen, Celgene Corporation, Genentech, Janssen Oncology, and Takeda Oncology
and individuals like you who supported the IMF this year